Avantor and Catalent Enter Multi-Year Agreement

Article

Avantor and Catalent have entered into a multi-year supply and services agreement.

Avantor announced on Jan. 9, 2023 that it has entered into a multi-year supply and services agreement with Catalent. Under the agreement, Avantor will become the primary supplier of a broad range of laboratory supplies, clinical and productions materials, and services to Catalent. The agreement will expand the companies’ existing relationship and offer more choices to customers.

"We have seen firsthand that Avantor is a terrific partner that brings diverse capabilities and expertise across modalities and geographies, which is essential to meeting global health needs," said Alessandro Maselli, president and CEO, Catalent. "We look forward to deepening our work with the Avantor team to bring current and novel treatments to patients around the world."

"Catalent has built tremendous global capabilities and a reputation as a trusted collaborator to pharma, biotech, and consumer health partners throughout the development and production lifecycle," said Michael Stubblefield, president and CEO, Avantor. "We are pleased to expand our support for Catalent and enable efficiencies to accelerate science for their customers around the globe."

Source: Avantor

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Preeya Beczek, managing director and co-founder of Beczek.COM, chats about industry trends from 2024 and which of those might impact the industry in 2025, including the big trend of AI.
Kate Coleman, vice president regulatory affairs, quality and compliance, Arriello, chats about industry trends and technological advances.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Related Content
© 2025 MJH Life Sciences

All rights reserved.